These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 8521296)

  • 61. TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines.
    Silva DAAD; Silva MVD; Barros CCO; Alexandre PBD; Timóteo RP; Catarino JS; Sales-Campos H; Machado JR; Rodrigues DBR; Oliveira CJ; Rodrigues V
    PLoS One; 2018; 13(3):e0194430. PubMed ID: 29543912
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Thalidomide: rationale for renewed use in immunological disorders.
    Schuler U; Ehninger G
    Drug Saf; 1995 Jun; 12(6):364-9. PubMed ID: 8527011
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Interferon-gamma and tumour necrosis factor-alpha production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis.
    de Castro Cunha RM; Kallas EG; Rodrigues DS; Nascimento Burattini M; Salomao R
    Clin Exp Immunol; 2005 Jun; 140(3):491-7. PubMed ID: 15932510
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunomodulatory assays to study structure-activity relationships of thalidomide.
    Shannon EJ; Morales MJ; Sandoval F
    Immunopharmacology; 1997 Jan; 35(3):203-12. PubMed ID: 9043933
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression.
    Noman AS; Koide N; Hassan F; I-E-Khuda I; Dagvadorj J; Tumurkhuu G; Islam S; Naiki Y; Yoshida T; Yokochi T
    Innate Immun; 2009 Feb; 15(1):33-41. PubMed ID: 19201823
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Potential mechanisms of benefit with thalidomide in chronic heart failure.
    Aukrust P; Yndestad A; Damås JK; Ueland T; Øie E; Gullestad L
    Am J Cardiovasc Drugs; 2007; 7(2):127-34. PubMed ID: 17503883
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study.
    Schoeman JF; Springer P; van Rensburg AJ; Swanevelder S; Hanekom WA; Haslett PA; Kaplan G
    J Child Neurol; 2004 Apr; 19(4):250-7. PubMed ID: 15163089
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin.
    Milazzo L; Biasin M; Gatti N; Piacentini L; Niero F; Zanone Poma B; Galli M; Moroni M; Clerici M; Riva A
    Am J Gastroenterol; 2006 Feb; 101(2):399-402. PubMed ID: 16454849
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevention and reversal of tumor cell-induced monocyte deactivation by cytokines, purified protein derivative (PPD), and anti-IL-10 antibody.
    Baj-Krzyworzeka M; Baran J; Szatanek R; Stankiewicz D; Siedlar M; Zembala M
    Cancer Immun; 2004 Aug; 4():8. PubMed ID: 15327279
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effect of thalidomide and 2 analogs on collagen induced arthritis.
    Oliver SJ; Cheng TP; Banquerigo ML; Brahn E
    J Rheumatol; 1998 May; 25(5):964-9. PubMed ID: 9598899
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure.
    Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B
    J Card Fail; 2002 Oct; 8(5):306-14. PubMed ID: 12411981
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis.
    Takashima T; Ueta C; Tsuyuguchi I; Kishimoto S
    Infect Immun; 1990 Oct; 58(10):3286-92. PubMed ID: 2205576
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New therapies for heart failure: is thalidomide the answer?
    Davey PP; Ashrafian H
    QJM; 2000 May; 93(5):305-11. PubMed ID: 10825407
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial.
    Wallis RS; Nsubuga P; Whalen C; Mugerwa RD; Okwera A; Oette D; Jackson JB; Johnson JL; Ellner JJ
    J Infect Dis; 1996 Oct; 174(4):727-33. PubMed ID: 8843209
    [TBL] [Abstract][Full Text] [Related]  

  • 75. (S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects.
    Nishimura K; Hashimoto Y; Iwasaki S
    Chem Pharm Bull (Tokyo); 1994 May; 42(5):1157-9. PubMed ID: 8069968
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs.
    Goosen C; Laing TJ; du Plessis J; Goosen TC; Rao TB; Flynn GL
    Pharm Res; 2002 Aug; 19(8):1232-5. PubMed ID: 12240951
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thalidomide in inflammatory bowel disease: too little, too soon.
    Selby W
    J Gastroenterol Hepatol; 2002 Mar; 17(3):233-5. PubMed ID: 11982691
    [No Abstract]   [Full Text] [Related]  

  • 78. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
    Gordon JN; Trebble TM; Ellis RD; Duncan HD; Johns T; Goggin PM
    Gut; 2005 Apr; 54(4):540-5. PubMed ID: 15753541
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Thalidomide use is associated with weight gain in HIV-1-positive clients.
    Sharp M; Getty J; Klausner JD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(5):392. PubMed ID: 9342262
    [No Abstract]   [Full Text] [Related]  

  • 80. [Novel biological response modifiers: phthalimides with TNF-alpha production regulating activity].
    Miyachi H; Azuma A; Hashimoto Y
    Yakugaku Zasshi; 1997 Feb; 117(2):91-107. PubMed ID: 9084226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.